CoChat

Prevalence of sarcopenia in patients with solid tumors: A meta‐analysis based on 81,814 patients

Open access
Surov, Alexey, Wienke, Andreas · 2022 · Journal of Parenteral and Enteral Nutrition

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 10 sources its claims cite is checked for support yet.

Abstract

Background: The purpose of the present meta‐analysis was to analyze the prevalence of sarcopenia on staging computed tomography (CT) in patients with different malignant solid tumors and in different oncologic settings based on a large sample. Methods: MEDLINE, Cochrane, and SCOPUS literature databases were screened for prevalence of sarcopenia in oncologic patients up to December 2021. Overall, 280 studies met the inclusion criteria. The methodological quality of the involved studies was checked according to the Quality Assessment of Diagnostic Studies instrument. The meta‐analysis was undertaken by using RevMan 5.4 software. DerSimonian and Laird random‐effects models with inverse‐variance weights were used. Results: The included 280 studies comprised 81,814 patients with different tumors. The prevalence of sarcopenia over all included studies was 35.3%. A prevalence of sarcopenia >50% was identified in esophageal cancer, urothelial cancer, cholangiocarcinoma, prostate cancer, sarcomas, and thyroid cancer. In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%. In colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer, the prevalence of low skeletal muscle mass was <35%. In curative setting, the prevalence of sarcopenia was 39.6% and in palliative setting, it was 49.2% ( P < 0.001). Conclusions: Sarcopenia is a frequent condition in oncology with a prevalence of 35.3%. The prevalence of sarcopenia is higher in palliative setting vs curative setting. The prevalence of sarcopenia is also different in different tumors.

Overview

CoChat Summary

TL;DR

This meta-analysis of 280 studies and 81,814 patients found an overall prevalence of sarcopenia/low skeletal muscle mass (LSMM) on staging CT of 35.3% in solid tumors. Prevalence varied by tumor type and was higher in palliative (49.2%) than curative (39.6%) settings (P < 0.001).

Key findings

  • Overall sarcopenia/LSMM prevalence was 35.3% (95% CI 34.9–35.6) across 280 studies and 81,814 patients; prevalence ranged from 28.3% in colorectal cancer to 61.0% in prostate cancer.
  • Prevalence >50% was identified in prostate cancer, esophageal cancer, urothelial cancer, cholangiocarcinoma, sarcomas, and thyroid cancer; 35%–50% in head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer; <35% in colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer.
  • In curative setting (51,751 patients, 63.3% of all patients), prevalence was 39.6%; in palliative setting (7,476 patients, 9.1%), prevalence was 49.2% (P < 0.001). The Results text also reports palliative prevalence as 49.68%, and the Discussion as 49.4%.
  • Sarcopenia definitions were heterogeneous: 75.9% of patients (62,070) were assessed with different cutoffs ranging from 23 to 47 cm²/m² in women and 29.1 to 63.94 cm²/m² in men; Prado cutoffs were used in 12.5%, BMI-adjusted cutoffs in 7.3%, and 41/43 cm²/m² cutoffs in 4.3%.

Methods

  • Systematic review and meta-analysis; MEDLINE, Cochrane, and SCOPUS were screened up to December 2021 using PRISMA, yielding 8,279 records and 280 included studies.
  • Inclusion criteria were original investigations of adult patients with malignant solid tumors, LSMM diagnosed on pretreatment CT by skeletal muscle index (SMI) at lumbar level 3, reported prevalence, study origin, and tumor setting (curative or palliative); exclusions included reviews, experimental studies, case reports, non-English articles, pediatric patients, non-CT diagnosis, and non-SMI L3 measurements.
  • Meta-analysis used DerSimonian and Laird random-effects models with inverse-variance weights in RevMan 5.4; methodological quality was assessed with QUADAS-2, and publication bias was examined with a funnel plot and Egger test.

Limitations

  • Stated by the paper: English-language studies only; most included studies were retrospective (192/280, 68.6%); publication bias was present (Egger test P = 0.001); only studies estimating sarcopenia on CT using SMI at L3 were included, excluding studies using sentinel muscles such as psoas or pectoral muscle.
  • Stated by the paper: patient numbers were small for thyroid cancer (257) and melanoma (115), only one study each was reported for endometrial cancer and uterine cervical cancer, and the text states no eligible studies were identified for sarcomas, thymic cancer, adrenal gland cancer, and mesotheliomas—although Table 2 lists 2 sarcoma studies (n = 252).
  • Evident from the text: SMI cutoffs were highly heterogeneous (75.9% of patients assessed with different cutoffs; ranges 23–47 cm²/m² in women and 29.1–63.94 cm²/m² in men), and palliative-setting prevalence is reported inconsistently as 49.2%, 49.68%, and 49.4% across the abstract, Results, and Discussion.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/jpen.2415

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY-NC-ND · From the PDF
Image 2
CC-BY-NC-ND · From the PDF
FIGURE 3 Funnel plot. There is publication bias among the included studies . The vertical line represents the overall proportion of sarcopenia.
FIGURE 3 Funnel plot. There is publication bias among the included studies . The vertical line represents the overall proportion of sarcopenia.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 7 Not checked · 27 Own results and interpretations

8 more claims

Create a free account to see all 34 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 8
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 8 · the rest aren’t loaded

3 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 26 references

Cited by

See all 138

Metadata

Authors
Surov, A., & Wienke, A.
Affiliations
  • Otto-von-Guericke-Universität Magdeburg (DE)
  • Martin Luther University Halle-Wittenberg (DE)
Corresponding author
Surov, Alexey
Venue
Journal of Parenteral and Enteral Nutrition
Publisher
Wiley
Published
2022-06-19
Volume
46
Issue
8
Pages
1761-1768
ISSN
  • 0148-6071 (ISSN-L)
  • 1941-2444
OpenAlex
W4281688637
Cited by
138
References
25
Citations by year
2026: 40 · 2025: 38 · 2024: 36 · 2023: 21 · 2022: 3
FWCI
12.66
Type
journal article
Language
en
Open access
Locations
  • Journal of Parenteral and Enteral Nutrition (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
Keywords
sarcopenia, solid tumors, prevalence, computed tomography staging, skeletal muscle mass, cancer cachexia, palliative care, curative cancer treatment, esophageal cancer, prostate cancer, head and neck squamous cell carcinoma, lung cancer, colorectal cancer, breast cancer
MeSH terms
Humans, Male, Pancreatic Neoplasms, Tomography, X-Ray Computed, Prevalence, Databases, Factual, Muscle, Skeletal, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of sarcopenia in patients with solid tumors: A meta‐analysis based on 81,814 patients. https://app.cochat.ai/papers/10.1002/jpen.2415
The paper
Surov, A., & Wienke, A. (2022). Prevalence of sarcopenia in patients with solid tumors: A meta‐analysis based on 81,814 patients. Journal of Parenteral and Enteral Nutrition. https://doi.org/10.1002/jpen.2415

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.